Observational analysis assesses treatment timing impact in acute myeloid leukemia, suggesting biology-informed decisions improve patient outcomes.
TDT should be viewed as a biology-adapted decision rather than an urgency metric: short, purposeful delays to complete genomic profiling can optimize treatment selection without harming outcomes, whereas system-driven delays remain detrimental and inequitable.
No takes yet. Share an insight, caveat, or question.
Molica et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: